litlas
Log inCreate account

Matthew W. Johnson

Active 2002–2025

Also published as
Matthew W Johnson
114
Papers
23,070
Citations
72
h-index
100
i10-index

Citations

Citations per year for Matthew W. Johnson1986: 1 citations2002: 1 citations2003: 6 citations2004: 12 citations2005: 18 citations2006: 26 citations2007: 24 citations2008: 40 citations2009: 50 citations2010: 36 citations2011: 72 citations2012: 74 citations2013: 78 citations2014: 123 citations2015: 146 citations2016: 211 citations2017: 248 citations2018: 314 citations2019: 526 citations2020: 866 citations2021: 1,014 citations2022: 1,265 citations2023: 847 citations2024: 1,305 citations2025: 572 citations2026: 31 citations1987–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,726 citing papers, 37.6% of this breakdownUnited Kingdom: 513 citing papers, 11.2% of this breakdownCanada: 288 citing papers, 6.3% of this breakdownGermany: 195 citing papers, 4.3% of this breakdownAustralia: 192 citing papers, 4.2% of this breakdownSwitzerland: 169 citing papers, 3.7% of this breakdownNetherlands: 160 citing papers, 3.5% of this breakdownSpain: 120 citing papers, 2.6% of this breakdownItaly: 112 citing papers, 2.4% of this breakdownChina: 105 citing papers, 2.3% of this breakdownBrazil: 98 citing papers, 2.1% of this breakdownFrance: 92 citing papers, 2% of this breakdown
0%37.6%Other 17.8%

Institutions

Fields

  • Psychology59.9%
  • Medicine12.7%
  • Neuroscience9.5%
  • Biochemistry, Genetics and Molecular Biology5.1%
  • Computer Science4.2%
  • Decision Sciences3.8%
  • Other4.8%

Topics

  • Psychedelics and Drug Studies18.5%
  • Neurotransmitter Receptor Influence on Behavior9.8%
  • Chemical synthesis and alkaloids7.1%
  • Forensic Toxicology and Drug Analysis5.7%
  • Pain Management and Placebo Effect2.9%
  • Biochemical Analysis and Sensing Techniques2.5%
  • Other53.5%

Coauthors

All papers

Open in search
  1. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

    Authors: Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, Annie Umbricht, William A. Richards, Brian D. Richards, Mary P Cosimano, Margaret A. Klinedinst - Journal of Psychopharmacology 2016 cited by 2,163

  2. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

    Authors: Alan K. Davis, Frederick S. Barrett, Darrick G. May, Mary P Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Patrick H. Finan, Roland R. Griffiths - JAMA Psychiatry 2020 cited by 1,258

  3. Single-Dose Psilocybin Treatment for Major Depressive Disorder

    Authors: Charles L. Raison, Gerard Sanacora, Joshua Woolley, Keith G. Heinzerling, Boadie W. Dunlop, Randall Brown, Rishi Kakar, Michael Hassman, Rupal Trivedi, Reid Robison, Natalie Gukasyan, Sandeep M. Nayak, Xiaojue Hu, Kelley C. O’Donnell, Benjamin Kelmendi, Jordan Sloshower, Andrew Penn, Ellen Bradley, Daniel F. Kelly, Tanja Mletzko, Christopher R. Nicholas, Paul R. Hutson, Gary Tarpley, Malynn Utzinger, Kelsey Lenoch, Kasia Warchol, Theraysa Gapasin, Mike C. Davis, Courtney Nelson-Douthit, Steffanie H Wilson, Carrie Brown, William Linton, Matthew W. Johnson, Stephen Ross, Roland R. Griffiths - JAMA 2023 cited by 484

  4. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

    Authors: Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, Mary P Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2022 cited by 413

  5. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction

    Authors: Matthew W. Johnson, Albert Garcia‐Romeu, Mary P Cosimano, Roland R. Griffiths - Journal of Psychopharmacology 2014 cited by 904

  6. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

    Authors: Frederick S. Barrett, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2015 cited by 630

  7. Long-term follow-up of psilocybin-facilitated smoking cessation

    Authors: Matthew W. Johnson, Albert Garcia‐Romeu, Roland R. Griffiths - The American Journal of Drug and Alcohol Abuse 2016 cited by 698

  8. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

    Authors: Frederick S. Barrett, Matthew P. Bradstreet, Jeannie‐Marie Leoutsakos, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2016 cited by 362

  9. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

    Authors: Roland R. Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards, Una D. McCann, Robert L. Jesse - Psychopharmacology 2011 cited by 937

  10. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

    Authors: Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert L. Jesse, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2016 cited by 539

  11. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial

    Authors: Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel, Tariq Ahmad, Paul Banim, James Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, J Gordon, Peter M. Irving, Matthew W. Johnson, Alexandra Kent, Klaartje Kok, Gordon W. Moran, Craig Mowat, Pritash Patel, C Probert, Tim Raine, Rebecca Saich, Abigail Seward, Dan Sharpstone, Melissa Smith, Sreedhar Subramanian, Sara Upponi, Alan A. Wiles, Horace R. Williams, Gijs R. van den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel, Tariq Ahmad, Paul Banim, James Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, J Gordon, Peter M. Irving, Matthew W. Johnson, Alexandra Kent, Klaartje Kok, Gordon W. Moran, Craig Mowat, Pritash Patel, C Probert, Tim Raine, Rebecca Saich, Abigail Seward, Dan Sharpstone, Melissa Smith, Sreedhar Subramanian, Sara Upponi, Alan A. Wiles, Horace R. Williams, Gijs van Den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Clare Allcock, Suhaylah Bhatti, Jonathan Blackwell, Robert Boulton-Jones, Matthew Brookes, Rhys O. Butcher, Jeffrey Butterworth, Karlena Champion, Rakesh Chaudhary, Andy Cole, Lauranne Derikx, Anjan Dhar, Mary Flowerdew, Rishi Goel, Ailsa Hart, R Hughes and 17 more - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 281

  12. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

    Authors: Katherine A. MacLean, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2011 cited by 905

  13. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

    Authors: Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, Roland R. Griffiths - Pharmacology & Therapeutics 2018 cited by 519

  14. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

    Authors: Roland R. Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards, Robert L. Jesse, Katherine A. MacLean, Frederick S. Barrett, Mary P Cosimano, Maggie A Klinedinst - Journal of Psychopharmacology 2017 cited by 526

  15. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

    Authors: Albert Garcia‐Romeu, Roland R. Griffiths, Matthew W. Johnson - Current Drug Abuse Reviews 2015 cited by 480

  16. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin

    Authors: Katherine A. MacLean, Jeannie‐Marie Leoutsakos, Matthew W. Johnson, Roland R. Griffiths - Journal for the Scientific Study of Religion 2012 cited by 412

  17. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

    Authors: Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, Jack E. Henningfield - Neuropharmacology 2018 cited by 344

  18. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

    Authors: Tehseen Noorani, Albert Garcia‐Romeu, Thomas Cody Swift, Roland R. Griffiths, Matthew W. Johnson - Journal of Psychopharmacology 2018 cited by 283

  19. Cessation and reduction in alcohol consumption and misuse after psychedelic use

    Authors: Albert Garcia‐Romeu, Alan K. Davis, Fire Erowid, Earth Erowid, Roland R. Griffiths, Matthew W. Johnson - Journal of Psychopharmacology 2019 cited by 284

  20. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

    Authors: Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, David S. Mathai, Sara So, Abigail Yaffe, Hadi Zaki, Trey Brasher, Matthew X. Lowe, Del R. P. Jolly, Frederick S. Barrett, Roland R. Griffiths, Justin C. Strickland, Matthew W. Johnson, Heather Jackson, Albert Garcia‐Romeu - Frontiers in Psychiatry 2023 cited by 85

  21. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

    Authors: Peter S. Hendricks, Christopher B. Thorne, C. Brendan Clark, David Coombs, Matthew W. Johnson - Journal of Psychopharmacology 2015 cited by 376

  22. Potential Therapeutic Effects of Psilocybin

    Authors: Matthew W. Johnson, Roland R. Griffiths - Neurotherapeutics 2017 cited by 301

  23. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

    Authors: Albert Garcia‐Romeu, Frederick S. Barrett, Theresa M. Carbonaro, Matthew W. Johnson, Roland R. Griffiths - Journal of Psychopharmacology 2021 cited by 99

  24. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource

    Authors: Christina Kapizioni, R Desoki, Danielle Lam, Karthiha Balendran, Eman AlSulais, Sreedhar Subramanian, Joanna Rimmer, Juan De La Revilla Negro, Holly Pavey, Laetitia Pele, Johanne Brooks, Gordon W. Moran, Peter M. Irving, Jimmy K. Limdi, Christopher A Lamb, UK IBD BioResource Investigators, Christopher Alexakis, Mohammed Allah-Ditta, Richard Appleby, Bijay Baburajan, Michelle Baker-Moffatt, Tyara Banerjee, Paul Banim, John Beckly, Roisin Bevan, Stuart Bloom, Monica Bose, Elaine Brinkworth, Johanne Brooks, Deborah Butcher, Jeffrey Butterworth, Mónica Chan, Katie Clark, A.T. Cole, Joseph Collum, Rachel Cooney, Fraser Cummings, Albert Davies, Aminda De Silva, John de Caestecker, Anjan Dhar, Stacey Duffy, Dharmaraj Durai, Cathryn Edwards, Stephen Foley, Tessa Glazebrook, John Gordon, Michael Grimes, Anton Gunasekera, Laura Hancock, Mina Hanna, Ailsa Hart, Gini Hay, David Hobday, Patricia Hooper, Mark Jarvis, Babur Javaid, Matthew W. Johnson, Lijo Joy, Rzwan Kassam, Nick Kennedy, Alexandra Kent, Klaartje Kok, Konrad Koss, Nicola Lancaster, Jonathan Landy, Charlie W. Lees, Wendy Lewis, Stephen J. Lewis, Andrew A. Li, Alan Lobo, J Loehry, Chris Ewen MacDonald, Christopher Macdonald, George MacFaul, Zahid Mahmood, Dina Mansour, Simon D. McLaughlin, John McLaughlin, Yin Miao, Ajay Muddu, Charles Murray, Chuka Nwokolo, Susan O’Sullivan, A.J. Oglesby, Simon Panter, Vinod Patel, Linda Patterson, Ruth Penn, Anne Phillips, Kath Phillis, Richard Pollok, Sam Powles, Cathryn Preston, Monira Rahman, Arvind Ramadas, John Ramage, S. Ramakrishnan, Jack Satsangi, John B. Saunders and 34 more - Journal of Crohn s and Colitis 2023 cited by 110